WO2008081774A1 - Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone - Google Patents

Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone Download PDF

Info

Publication number
WO2008081774A1
WO2008081774A1 PCT/JP2007/074822 JP2007074822W WO2008081774A1 WO 2008081774 A1 WO2008081774 A1 WO 2008081774A1 JP 2007074822 W JP2007074822 W JP 2007074822W WO 2008081774 A1 WO2008081774 A1 WO 2008081774A1
Authority
WO
WIPO (PCT)
Prior art keywords
risperidone
bitter
tablet
preparation
less
Prior art date
Application number
PCT/JP2007/074822
Other languages
French (fr)
Japanese (ja)
Inventor
Toshitada Toyoda
Chieko Imamoto
Yoshitaka Tomoda
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Priority to JP2008552107A priority Critical patent/JP5275815B2/en
Publication of WO2008081774A1 publication Critical patent/WO2008081774A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are: an orally disintegrating tablet; and a bitter-blocking preparation, each of which comprises risperidone. It is found that an orally disintegrating table having good disintegration property and ensured hardness can be produced by compressing and shaping a powder comprising risperidone, crystalline cellulose, an inorganic excipient, carmellose, and a lubricating agent in an amount of 0.8 wt% or less, preferably 0.5 wt% or less, more preferably 0.1 wt% or less per one tablet. Specifically disclosed are: a powdery/granular preparation produced by granulating an excipient and/or a disintegrating agent with a solution having a bitter-blocking base material dissolved and/or suspended therein and also having risperidone having a solubility in water of 1 g/mL or less (at 20˚C) dissolved or suspended therein; and a tablet produced by tabletting the powdery/granular preparation. The powdery/granule preparation and the tablet can block a bitter taste of risperidone.
PCT/JP2007/074822 2006-12-26 2007-12-25 Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone WO2008081774A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008552107A JP5275815B2 (en) 2006-12-26 2007-12-25 Orally disintegrating tablets and bitterness-suppressing preparations containing risperidone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-349336 2006-12-26
JP2006349336 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008081774A1 true WO2008081774A1 (en) 2008-07-10

Family

ID=39588457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074822 WO2008081774A1 (en) 2006-12-26 2007-12-25 Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone

Country Status (4)

Country Link
JP (2) JP5275815B2 (en)
KR (1) KR20090094319A (en)
TW (1) TW200835527A (en)
WO (1) WO2008081774A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013060392A (en) * 2011-09-13 2013-04-04 Sawai Pharmaceutical Co Ltd Oral disintegrant tablet containing risperidone and method for producing the same
WO2013115171A1 (en) * 2012-02-03 2013-08-08 旭化成ケミカルズ株式会社 Orally disintegrating tablet containing bitterness-masking granules
JP7572798B2 (en) 2019-06-06 2024-10-24 キョーリンリメディオ株式会社 Eszopiclone-containing tablets

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090094319A (en) * 2006-12-26 2009-09-04 시오노기 앤드 컴파니, 리미티드 Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123084A1 (en) * 2004-06-15 2005-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating pharmaceutical composition comprising risperidone
JP2006524650A (en) * 2003-04-16 2006-11-02 シントン・ベスローテン・フェンノートシャップ Orally disintegrating tablets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
JP3995202B2 (en) * 2002-08-14 2007-10-24 三重県 Turmeric composition for oral use
US20040162333A1 (en) * 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations
DE10355461A1 (en) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
KR20090094319A (en) * 2006-12-26 2009-09-04 시오노기 앤드 컴파니, 리미티드 Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524650A (en) * 2003-04-16 2006-11-02 シントン・ベスローテン・フェンノートシャップ Orally disintegrating tablets
WO2005123084A1 (en) * 2004-06-15 2005-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating pharmaceutical composition comprising risperidone

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013060392A (en) * 2011-09-13 2013-04-04 Sawai Pharmaceutical Co Ltd Oral disintegrant tablet containing risperidone and method for producing the same
WO2013115171A1 (en) * 2012-02-03 2013-08-08 旭化成ケミカルズ株式会社 Orally disintegrating tablet containing bitterness-masking granules
JPWO2013115171A1 (en) * 2012-02-03 2015-05-11 旭化成ケミカルズ株式会社 Orally disintegrating tablets containing bitter mask granules
US9744134B2 (en) 2012-02-03 2017-08-29 Asahi Kasei Chemicals Corporation Orally disintegrating tablet containing bitterness-masking granules
JP7572798B2 (en) 2019-06-06 2024-10-24 キョーリンリメディオ株式会社 Eszopiclone-containing tablets

Also Published As

Publication number Publication date
JP2013040199A (en) 2013-02-28
TW200835527A (en) 2008-09-01
JPWO2008081774A1 (en) 2010-04-30
KR20090094319A (en) 2009-09-04
JP5275815B2 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
JP5583012B2 (en) Intraoral quick disintegrating tablet and method for producing the same
WO2009043844A3 (en) Orodispersible tablets
MX2009013063A (en) Pharmaceutical formulation for the production of rapidly disintegrating tablets.
MXPA04012464A (en) Orally disintegrating tablets and process for obtaining them.
JP5342028B2 (en) Orally disintegrating tablets
EP2210591A3 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
HK1087948A1 (en) Fast water-sispersible domperidone tablets
WO2008148733A3 (en) Pharmaceutical formulation for the production of rapidly disintegrating tablets
HK1073263A1 (en) A process for the preparation of tablets from pharmaceutically active substances having unfavourabletabletting properties with a granulating liquid c omprising microcrystalline cellulose
MX2009014193A (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof.
WO2008079342A3 (en) Composition of and method for preparing orally disintegrating tablets
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
TW200740424A (en) Taste masking dosage form
JP4108605B2 (en) Amino acid-containing intraoral quick disintegrating tablet and method for producing the same
WO2008081774A1 (en) Orally disintegrating tablet and bitter-blocking preparation each comprising risperidone
JP4361597B2 (en) Disintegrant and tablets and granules containing the same
WO2007052307A3 (en) Stable solid oral dosage forms of valsartan
EP1658841A3 (en) Tablet excipient
JP2007161706A (en) Antyusan-containing tablet
JPWO2009054432A1 (en) Oral rapidly disintegrating pharmaceutical composition and method for producing the same
JP2015008639A (en) Manufacturing method for food tablet disintegrating in oral cavity
WO2017170763A1 (en) Disintegrable tablet and method for manufacturing same
CN105555316B (en) Disintegrating granule composition produced by two-stage wet granulation process and intraorally disintegrating tablet containing the same
WO2004037961A3 (en) Tablet of compacted particulate cleaning composition
JPWO2005099681A1 (en) Tablet containing branched-chain amino acid and method for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860051

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008552107

Country of ref document: JP

Ref document number: 1020097013265

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860051

Country of ref document: EP

Kind code of ref document: A1